Dan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dan Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zheng
Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou 310013, China
1 shared publication - Shaohong Lu
Engineering Research Center of Novel Vaccine of Zhejiang Province, Zhejiang Provincial Key Laboratory of High-level Biosafety and Biomedical Transformation, Hangzhou Medical College, China
1 shared publication - Yizhuo Zhang
Laboratory of Pathogen Biology, School of Basic Medicine and Forensics, Hangzhou Medical College , Hangzhou, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 31 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-8
Toxoplasmosis vaccines: what we have and where to go?
Despite recent major advances in developing effective vaccines against toxoplasmosis, finding new protective vaccination strategies remains a challenging and elusive goal as it is critical to prevent the disease. Over the past few years, various experimental approaches have shown that developing an effective vaccine against T. gondii is achievable. However, more remains unknown due to its complicated life cycle, difficulties in clinical translation, and lack of a standardized platform. This minireview summarizes the recent advances in the development of T. gondii vaccines and the main obstacles to developing a safe, effective and durable T. gondii vaccine. The successes and failures in developing and testing vaccine candidates for the T. gondii vaccine are also discussed, which may facilitate the future development of T. gondii vaccines.
- 31 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-8
Top Cited PapersOpen AccessToxoplasmosis vaccines: what we have and where to go?
Despite recent major advances in developing effective vaccines against toxoplasmosis, finding new protective vaccination strategies remains a challenging and elusive goal as it is critical to prevent the disease. Over the past few years, various experimental approaches have shown that developing an effective vaccine against T. gondii is achievable. However, more remains unknown due to its complicated life cycle, difficulties in clinical translation, and lack of a standardized platform. This minireview summarizes the recent advances in the development of T. gondii vaccines and the main obstacles to developing a safe, effective and durable T. gondii vaccine. The successes and failures in developing and testing vaccine candidates for the T. gondii vaccine are also discussed, which may facilitate the future development of T. gondii vaccines.